Karyopharm Therapeutics
KPTI
54 hedge funds and large institutions have $204M invested in Karyopharm Therapeutics in 2013 Q4 according to their latest regulatory filings, with 54 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$43.2M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$16.4M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$14.5M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$9.3M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$8.37M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Bank of America
Charlotte,
North Carolina
| $26K | +$21.3K | +77 | New |
|
|
TRCT
52
Tower Research Capital (TRC)
New York
| $9K | +$6.63K | +24 | New |
|
53
BNP Paribas Financial Markets
Paris,
France
| $2.2K | +$1.66K | +6 | New |
|
54
Barclays
London,
United Kingdom
| $2K | +$2.21K | +8 | New |
|
KPTI Hedge Fund Activity: Q4 2013 in Review
54 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q4 2013, worth a combined $204M.
Buyers outnumbered sellers: 54 funds opened new KPTI positions and 0 closed out — a net gain of 54 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $43.2M.
- 54 institutional investors held Karyopharm Therapeutics (KPTI) as of Q4 2013, up from 0 in Q3 2013.
- Funds reported $204M of Karyopharm Therapeutics stock for Q4 2013.
- 54 funds opened new Karyopharm Therapeutics positions in Q4 2013 and 0 closed out, a net change of +54 holders.
- The largest Karyopharm Therapeutics buyer in Q4 2013 was Fidelity Investments, an estimated $43.2M added.
Based on aggregated 13F filings for Q4 2013.